+1 (202) 780-3397
Epitope-specific antibody profiling using novel multiplex immunoassay: A new generation of biomarker for food allergy
Joint Event on International Conference on Plastic and Cosmetic Surgery & International Conference on Biomarkers
March 11-12, 2019 | London, UK
Mayte Suarez Farinas
Icahn School of Medicine at Mount Sinai, USA
Scientific Tracks Abstracts : Case Rep Surg Invasive Proced
Abstract:
Identification of allergenic IgE epitopes is instrumental for
the advancement of diagnostic and prognostic tests for food
allergy. We have developed a novel Bead-Based Epitope Assay
(BBEA) that quantifies epitope-specific antibody binding (ESAB)
for multiple epitopes in a large number of samples. We show
that this assay had impressive reliability across replicates, high
reproducibility across laboratories, and is more reliable and
sensitive than current peptide microarray (MIA) technology.
The potential of BBEA as new tool for diagnosis, prognosis and
endotype discovery in peanut and milk allergy will be illustrated
in three applications that use BBEA-based IgE and IgG4 binding
to sequential allergenic epitopes.
Diagnosis of oral food challenges (OFC): Despite intense
resource utilization and inherent risk, OFC remain the gold
standard for clinical diagnosis of food allergy. Utilizing a cohort
of 185 high-risk children from the CoFAR study, we determined
their utility in predicting peanut allergy.
Prediction of allergy endotypes: Using BBEA profiles from 89
milk-allergic children who tolerated different forms of milk
products we used machine learning methods to distinguish
them into four endotypes: reactive to baked-, fermented-, or
whole-milk, and outgrown. BBEA’s performance was twice that
of the serum component proteins (41.9%) in training, achieving
a performance in the validation set (n=21) of 86%(AUC=0.89).
Prognosis in oral immunotherapy: Although recent clinical
trials have shown that the majority of patients undergoing oral
immunotherapy develop desensitization only half would achieve
“sustained unresponsiveness” after therapy discontinuation.
Using serum from 47 subjects prior to treatment, we show
that epitope-specific IgE alone was more accurate in predicting
sustained unresponsiveness than standard serum component
proteins (average AUC of 97% vs 80%).
This work highlights the potential of BBEA biomarker discovery
to develop precision medicine approaches to diagnose allergy,
predict severity endotype, and screen patients who would
receive the most benefit from oral immunotherapy.
Biography:
Mayte Suarez Farinas, is currently an associate professor at the center for biostatistics and the department of genetics and genomics science of the Icahn school of medicine at Mount Sinai, New York. She received a master’s in mathematics from the University of Havana, Cuba and in 2003, a PhD degree in quantitative analysis from the Pontifical Catholic University of Rio de Janeiro, Brazil. In the last three years she teams up with food allergy investigators at the Icahn School of Medicine at Mount Sinai and Allergenis to develop a high-throughput assay for epitope profiling and use it to develop precision medicine algorithms to diagnosis, endotype and response to immunotherapy in patients with milk and peanut allergy. She has over 140 publications that have been cited in over 4000 articles, with an H-index of 44 and has been serving as reviewer of reputed journals and grant funding agencies.
E-mail: mayte.suarezfarinas@mssm.edu
PDF HTML